Pharma        CDMO Services
Pharma

Innovation

Our innovation model focuses on improving lives through innovative treatments. It is based on four main ideas:

Specialty and Complex Areas: Targeting severe and complex conditions in specialty therapeutic areas to meet unmet medical needs.

Collaborative Partnerships: Working closely with experts from public and private sectors to enhance patient care and health outcomes.

Late-Stage Development: Prioritizing late-stage clinical trials and managing the lifecycle of medicines to ensure effective treatments reach patients.

Efficient Operations: Shifting focus from basic research to clinical development, using efficient and sustainable systems supported by global scientific, medical, and regulatory expertise.

Our pipeline encompasses clinical development of new molecular and biological entities and life cycle extension projects for existing products.


Description
Product - Brand
Status
Geography
Treatment of severe Chronic in adults requiring intrathecal analgesia

Prialt®

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

Europe

Treatment of neuroendocrine tumors of pancreatic origin

Zanosar®

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

EU, Latin America, Middle East and North Africa region

Agent preparing the patient for a bone marrow transplant in oncohematological diseases

Thiotepa Riemser®

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

China, LatAm

Symptomatic treatment of malignant tumors of the adrenal glands

Lysodren ®

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

Europe, United States, China, Latin America

Treatment of Cushing's syndrome

Metopirone®

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

Europe, United States, China, Latin America

Treatment of Cushing's syndrome

Ketoconazol ESTEVE®

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

Europe

Treatment for Acute Pain

Velyntra®

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

Spain

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

EU, Latin America, Middle East and North Africa region

  1. Preclinical development
  2. Clinical development
  3. Regulatory expansion
  4. Marketed
  5. Post-marketing

China

Internal projects with public financing

The internal projects developed in collaboration with multiple centres were financed mainly with Esteve's own resources, to which some competitive public grants has been added. Esteve has neither requested nor has it ever received funding from patients' associations or private individuals.

E-52862 has received grants from the Spain's Ministry of Economy and Competitiveness, via the Centre for Industrial Technological Development (CDTI) for clinical validation in neuropathic pain, as well as the projects Multimodal-1, Multimodal-2, Multimodal-3, Multimodal-5 and Sigma-1 new indications, that have also been partially co-financed by the European Union via the European Regional Development Fund (ERDF).

Project E-58425 has received a grant by the Catalonia Trade & Investment Agency (ACC1Ó) of the Generalitat de Catalunya as part of the line of loans for industrial innovation and experimental development projects via the Catalan Institute of Finance (ICF).

The Sanfilippo project has received grants from the Spain's Ministry of Economy and Competitiveness and the Ministry of Health, Social Policy and Equality, in competitive calls for research projects, in which the project was recognized for its scientific excellence.

The Phenopain project (Development of In Vitro Phenotypic Models of Pain and its Application to the Screening of High Throughput Compounds) aims to generate in vitro translational models for application to drug discovery to predict the therapeutic profile of new drugs in pain.

Phenopain has received funding from the RETOS-COLABORACIÓN program of the Ministry of Economy and Competitiveness and has been co-financed by the European Union through the European Regional Development Fund (FEDER).